Stephen David Prior - 26 Feb 2025 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Strategy Officer
Signature
/s/ Lucy Day, Attorney-in-Fact for Stephen David Prior
Issuer symbol
ANTX
Transactions as of
26 Feb 2025
Net transactions value
$0
Form type
4
Filing time
28 Feb 2025, 16:19:36 UTC
Previous filing
07 Jan 2025
Next filing
06 Nov 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Award $0 +28,000 +84% $0.000000 61,313 26 Feb 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANTX Stock Option (right to buy) Award $0 +56,000 $0.000000 56,000 26 Feb 2025 Common Stock 56,000 $1.13 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date.
F2 Includes (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 and (b) 12,031 RSUs which shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.
F3 The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date.